JP2018533363A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018533363A5 JP2018533363A5 JP2018521543A JP2018521543A JP2018533363A5 JP 2018533363 A5 JP2018533363 A5 JP 2018533363A5 JP 2018521543 A JP2018521543 A JP 2018521543A JP 2018521543 A JP2018521543 A JP 2018521543A JP 2018533363 A5 JP2018533363 A5 JP 2018533363A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- hematopoietic
- derived
- pluripotent stem
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000130 stem cell Anatomy 0.000 claims description 121
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 77
- 210000004027 cell Anatomy 0.000 claims description 71
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 62
- 239000000203 mixture Substances 0.000 claims description 56
- 230000003394 haemopoietic effect Effects 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 48
- 210000000822 natural killer cell Anatomy 0.000 claims description 44
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 38
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 38
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 29
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 29
- 210000003038 endothelium Anatomy 0.000 claims description 28
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 17
- 210000000581 natural killer T-cell Anatomy 0.000 claims description 13
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 10
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 10
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 8
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 8
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 6
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 6
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 6
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 claims description 5
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 claims description 5
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 claims description 5
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 claims description 5
- 238000012790 confirmation Methods 0.000 claims description 4
- 239000002243 precursor Substances 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims 51
- 239000012190 activator Substances 0.000 claims 43
- 239000003112 inhibitor Substances 0.000 claims 43
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 41
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims 39
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 39
- 210000001704 mesoblast Anatomy 0.000 claims 38
- 230000004069 differentiation Effects 0.000 claims 35
- 101000844802 Lacticaseibacillus rhamnosus Teichoic acid D-alanyltransferase Proteins 0.000 claims 32
- 239000011435 rock Substances 0.000 claims 30
- 239000000427 antigen Substances 0.000 claims 28
- 102000036639 antigens Human genes 0.000 claims 28
- 108091007433 antigens Proteins 0.000 claims 28
- 102000004127 Cytokines Human genes 0.000 claims 23
- 108090000695 Cytokines Proteins 0.000 claims 23
- 102100020880 Kit ligand Human genes 0.000 claims 23
- 101710177504 Kit ligand Proteins 0.000 claims 23
- 239000003102 growth factor Substances 0.000 claims 23
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 22
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 22
- 230000002068 genetic effect Effects 0.000 claims 21
- 230000037361 pathway Effects 0.000 claims 19
- 229940122531 Anaplastic lymphoma kinase inhibitor Drugs 0.000 claims 16
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 claims 16
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 claims 16
- 206010028980 Neoplasm Diseases 0.000 claims 16
- 108091005735 TGF-beta receptors Proteins 0.000 claims 16
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 claims 16
- 102100027188 Thyroid peroxidase Human genes 0.000 claims 15
- 101710113649 Thyroid peroxidase Proteins 0.000 claims 15
- 230000001225 therapeutic effect Effects 0.000 claims 14
- 102000001267 GSK3 Human genes 0.000 claims 13
- 108060006662 GSK3 Proteins 0.000 claims 13
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 claims 13
- 102000005962 receptors Human genes 0.000 claims 13
- 108020003175 receptors Proteins 0.000 claims 13
- 108010092408 Eosinophil Peroxidase Proteins 0.000 claims 12
- 102100021592 Interleukin-7 Human genes 0.000 claims 12
- 108010002586 Interleukin-7 Proteins 0.000 claims 12
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 claims 12
- 102000013814 Wnt Human genes 0.000 claims 12
- 108050003627 Wnt Proteins 0.000 claims 12
- 230000024245 cell differentiation Effects 0.000 claims 12
- 102000026633 IL6 Human genes 0.000 claims 11
- 102000003815 Interleukin-11 Human genes 0.000 claims 11
- 108090000177 Interleukin-11 Proteins 0.000 claims 11
- 108090001005 Interleukin-6 Proteins 0.000 claims 11
- 230000004663 cell proliferation Effects 0.000 claims 11
- 101001033279 Homo sapiens Interleukin-3 Proteins 0.000 claims 10
- 102100039064 Interleukin-3 Human genes 0.000 claims 10
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 9
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 9
- 210000002865 immune cell Anatomy 0.000 claims 9
- -1 targeting modality Proteins 0.000 claims 8
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims 7
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 7
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims 7
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 claims 7
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 7
- 238000011161 development Methods 0.000 claims 7
- 230000018109 developmental process Effects 0.000 claims 7
- 210000002242 embryoid body Anatomy 0.000 claims 7
- 230000008672 reprogramming Effects 0.000 claims 7
- 102000003812 Interleukin-15 Human genes 0.000 claims 6
- 108090000172 Interleukin-15 Proteins 0.000 claims 6
- 101150008942 J gene Proteins 0.000 claims 6
- 210000001357 hemopoietic progenitor cell Anatomy 0.000 claims 6
- 230000001939 inductive effect Effects 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- 238000001167 microscope projection photolithography Methods 0.000 claims 6
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 230000008707 rearrangement Effects 0.000 claims 6
- 230000000717 retained effect Effects 0.000 claims 6
- 102100025877 Complement component C1q receptor Human genes 0.000 claims 5
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 5
- 101000933665 Homo sapiens Complement component C1q receptor Proteins 0.000 claims 5
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 claims 5
- 238000012217 deletion Methods 0.000 claims 5
- 230000037430 deletion Effects 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 230000003511 endothelial effect Effects 0.000 claims 5
- 230000006698 induction Effects 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims 4
- 229940124647 MEK inhibitor Drugs 0.000 claims 4
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 4
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 4
- 238000011467 adoptive cell therapy Methods 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 238000002512 chemotherapy Methods 0.000 claims 4
- 230000000139 costimulatory effect Effects 0.000 claims 4
- 210000002889 endothelial cell Anatomy 0.000 claims 4
- 230000001965 increasing effect Effects 0.000 claims 4
- 238000004264 monolayer culture Methods 0.000 claims 4
- 230000002688 persistence Effects 0.000 claims 4
- 210000004881 tumor cell Anatomy 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 3
- 102000012804 EPCAM Human genes 0.000 claims 3
- 101150084967 EPCAM gene Proteins 0.000 claims 3
- 108010055196 EphA2 Receptor Proteins 0.000 claims 3
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims 3
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 3
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 3
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 3
- 241000829111 Human polyomavirus 1 Species 0.000 claims 3
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims 3
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims 3
- 101150057140 TACSTD1 gene Proteins 0.000 claims 3
- 108091023040 Transcription factor Proteins 0.000 claims 3
- 102000040945 Transcription factor Human genes 0.000 claims 3
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 230000015572 biosynthetic process Effects 0.000 claims 3
- 239000012636 effector Substances 0.000 claims 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 3
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 238000003780 insertion Methods 0.000 claims 3
- 230000037431 insertion Effects 0.000 claims 3
- 210000002540 macrophage Anatomy 0.000 claims 3
- 210000003071 memory t lymphocyte Anatomy 0.000 claims 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 3
- 210000000440 neutrophil Anatomy 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 230000004797 therapeutic response Effects 0.000 claims 3
- 241000701161 unidentified adenovirus Species 0.000 claims 3
- 102100026882 Alpha-synuclein Human genes 0.000 claims 2
- 102100030346 Antigen peptide transporter 1 Human genes 0.000 claims 2
- 102100030343 Antigen peptide transporter 2 Human genes 0.000 claims 2
- 102100027314 Beta-2-microglobulin Human genes 0.000 claims 2
- 102100020986 DNA-binding protein RFX5 Human genes 0.000 claims 2
- 102100021044 DNA-binding protein RFXANK Human genes 0.000 claims 2
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 claims 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 2
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims 2
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 claims 2
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 2
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims 2
- 101001075432 Homo sapiens DNA-binding protein RFX5 Proteins 0.000 claims 2
- 101001075464 Homo sapiens DNA-binding protein RFXANK Proteins 0.000 claims 2
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 claims 2
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 2
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims 2
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 2
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 2
- 101000979565 Homo sapiens Protein NLRC5 Proteins 0.000 claims 2
- 101001075466 Homo sapiens Regulatory factor X-associated protein Proteins 0.000 claims 2
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 claims 2
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 2
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 2
- 102000017578 LAG3 Human genes 0.000 claims 2
- 108010023335 Member 2 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 2
- 102100023432 Protein NLRC5 Human genes 0.000 claims 2
- 102100021043 Regulatory factor X-associated protein Human genes 0.000 claims 2
- 108091008874 T cell receptors Proteins 0.000 claims 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 2
- 101800000849 Tachykinin-associated peptide 2 Proteins 0.000 claims 2
- 102100028082 Tapasin Human genes 0.000 claims 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 230000000981 bystander Effects 0.000 claims 2
- 239000003596 drug target Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000011365 genetic imprinting Effects 0.000 claims 2
- 230000002519 immonomodulatory effect Effects 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 238000010899 nucleation Methods 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 230000009467 reduction Effects 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 230000004083 survival effect Effects 0.000 claims 2
- 108010059434 tapasin Proteins 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 230000035899 viability Effects 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 102100026423 Adhesion G protein-coupled receptor E5 Human genes 0.000 claims 1
- 102100022749 Aminopeptidase N Human genes 0.000 claims 1
- 102100022014 Angiopoietin-1 receptor Human genes 0.000 claims 1
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 claims 1
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 claims 1
- 102100037086 Bone marrow stromal antigen 2 Human genes 0.000 claims 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims 1
- 102100022595 Broad substrate specificity ATP-binding cassette transporter ABCG2 Human genes 0.000 claims 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims 1
- 102100037917 CD109 antigen Human genes 0.000 claims 1
- 102100024210 CD166 antigen Human genes 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 102100035793 CD83 antigen Human genes 0.000 claims 1
- 102100037904 CD9 antigen Human genes 0.000 claims 1
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical group CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 claims 1
- 102100025805 Cadherin-1 Human genes 0.000 claims 1
- 102100029761 Cadherin-5 Human genes 0.000 claims 1
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 claims 1
- 102000000844 Cell Surface Receptors Human genes 0.000 claims 1
- 108010001857 Cell Surface Receptors Proteins 0.000 claims 1
- 102100023126 Cell surface glycoprotein MUC18 Human genes 0.000 claims 1
- 102100025680 Complement decay-accelerating factor Human genes 0.000 claims 1
- 102100032768 Complement receptor type 2 Human genes 0.000 claims 1
- 101710093674 Cyclic nucleotide-gated cation channel beta-1 Proteins 0.000 claims 1
- 102100033553 Delta-like protein 4 Human genes 0.000 claims 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims 1
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 claims 1
- 102100037241 Endoglin Human genes 0.000 claims 1
- 102100030024 Endothelial protein C receptor Human genes 0.000 claims 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 1
- 102100028113 Granulocyte-macrophage colony-stimulating factor receptor subunit alpha Human genes 0.000 claims 1
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 claims 1
- 108010024164 HLA-G Antigens Proteins 0.000 claims 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims 1
- 101000718243 Homo sapiens Adhesion G protein-coupled receptor E5 Proteins 0.000 claims 1
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 claims 1
- 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 claims 1
- 101000773743 Homo sapiens Angiotensin-converting enzyme Proteins 0.000 claims 1
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 claims 1
- 101000740785 Homo sapiens Bone marrow stromal antigen 2 Proteins 0.000 claims 1
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 claims 1
- 101000777558 Homo sapiens C-C chemokine receptor type 10 Proteins 0.000 claims 1
- 101000738399 Homo sapiens CD109 antigen Proteins 0.000 claims 1
- 101000980840 Homo sapiens CD166 antigen Proteins 0.000 claims 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 claims 1
- 101000794587 Homo sapiens Cadherin-5 Proteins 0.000 claims 1
- 101000981093 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 1 Proteins 0.000 claims 1
- 101000623903 Homo sapiens Cell surface glycoprotein MUC18 Proteins 0.000 claims 1
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 claims 1
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 claims 1
- 101000872077 Homo sapiens Delta-like protein 4 Proteins 0.000 claims 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims 1
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 claims 1
- 101000881679 Homo sapiens Endoglin Proteins 0.000 claims 1
- 101001012038 Homo sapiens Endothelial protein C receptor Proteins 0.000 claims 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims 1
- 101000878602 Homo sapiens Immunoglobulin alpha Fc receptor Proteins 0.000 claims 1
- 101001078158 Homo sapiens Integrin alpha-1 Proteins 0.000 claims 1
- 101000994378 Homo sapiens Integrin alpha-3 Proteins 0.000 claims 1
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 claims 1
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 claims 1
- 101001046677 Homo sapiens Integrin alpha-V Proteins 0.000 claims 1
- 101000599858 Homo sapiens Intercellular adhesion molecule 2 Proteins 0.000 claims 1
- 101001001420 Homo sapiens Interferon gamma receptor 1 Proteins 0.000 claims 1
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 claims 1
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 claims 1
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 claims 1
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 claims 1
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 claims 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 1
- 101001133085 Homo sapiens Sialomucin core protein 24 Proteins 0.000 claims 1
- 101000763314 Homo sapiens Thrombomodulin Proteins 0.000 claims 1
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 claims 1
- 101000764263 Homo sapiens Tumor necrosis factor ligand superfamily member 4 Proteins 0.000 claims 1
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 claims 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 claims 1
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 claims 1
- 101000622304 Homo sapiens Vascular cell adhesion protein 1 Proteins 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102100038005 Immunoglobulin alpha Fc receptor Human genes 0.000 claims 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims 1
- 102100025323 Integrin alpha-1 Human genes 0.000 claims 1
- 102100032819 Integrin alpha-3 Human genes 0.000 claims 1
- 102100032818 Integrin alpha-4 Human genes 0.000 claims 1
- 102100032816 Integrin alpha-6 Human genes 0.000 claims 1
- 102100022337 Integrin alpha-V Human genes 0.000 claims 1
- 102100033010 Integrin beta-5 Human genes 0.000 claims 1
- 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 claims 1
- 102100035678 Interferon gamma receptor 1 Human genes 0.000 claims 1
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 claims 1
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 claims 1
- 108010091221 Lymphotoxin beta Receptor Proteins 0.000 claims 1
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 claims 1
- 102000018697 Membrane Proteins Human genes 0.000 claims 1
- 108010052285 Membrane Proteins Proteins 0.000 claims 1
- 102100039373 Membrane cofactor protein Human genes 0.000 claims 1
- 102100038169 Musculin Human genes 0.000 claims 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 1
- 102100023064 Nectin-1 Human genes 0.000 claims 1
- 102000003729 Neprilysin Human genes 0.000 claims 1
- 108090000028 Neprilysin Proteins 0.000 claims 1
- 102100028762 Neuropilin-1 Human genes 0.000 claims 1
- 102000001753 Notch4 Receptor Human genes 0.000 claims 1
- 102100037589 OX-2 membrane glycoprotein Human genes 0.000 claims 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims 1
- 102100037265 Podoplanin Human genes 0.000 claims 1
- 101710118150 Podoplanin Proteins 0.000 claims 1
- 102100029740 Poliovirus receptor Human genes 0.000 claims 1
- 102100029198 SLAM family member 7 Human genes 0.000 claims 1
- 102100027744 Semaphorin-4D Human genes 0.000 claims 1
- 102100034258 Sialomucin core protein 24 Human genes 0.000 claims 1
- 210000000173 T-lymphoid precursor cell Anatomy 0.000 claims 1
- 102100026966 Thrombomodulin Human genes 0.000 claims 1
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 claims 1
- 102100025946 Transforming growth factor beta activator LRRC32 Human genes 0.000 claims 1
- 101710169732 Transforming growth factor beta activator LRRC32 Proteins 0.000 claims 1
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 claims 1
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 claims 1
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 claims 1
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 claims 1
- 102100040115 Tumor necrosis factor receptor superfamily member 10C Human genes 0.000 claims 1
- 102100022156 Tumor necrosis factor receptor superfamily member 3 Human genes 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 claims 1
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 claims 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 230000027455 binding Effects 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 238000002659 cell therapy Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 238000009795 derivation Methods 0.000 claims 1
- 230000009762 endothelial cell differentiation Effects 0.000 claims 1
- 210000003386 epithelial cell of thymus gland Anatomy 0.000 claims 1
- 230000000763 evoking effect Effects 0.000 claims 1
- 238000010362 genome editing Methods 0.000 claims 1
- 238000003881 globally optimized alternating phase rectangular pulse Methods 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 230000001146 hypoxic effect Effects 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 230000001976 improved effect Effects 0.000 claims 1
- 230000006872 improvement Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 108010068609 integrin alpha 9 beta 1 Proteins 0.000 claims 1
- 108010021518 integrin beta5 Proteins 0.000 claims 1
- 230000002601 intratumoral effect Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 239000002609 medium Substances 0.000 claims 1
- 230000001400 myeloablative effect Effects 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 108010048507 poliovirus receptor Proteins 0.000 claims 1
- 210000001978 pro-t lymphocyte Anatomy 0.000 claims 1
- 230000008569 process Effects 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 230000003716 rejuvenation Effects 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 210000001541 thymus gland Anatomy 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022000188A JP2022058480A (ja) | 2015-11-04 | 2022-01-04 | 造血細胞分化を誘導するための方法および組成物 |
| JP2024015135A JP2024054194A (ja) | 2015-11-04 | 2024-02-02 | 造血細胞分化を誘導するための方法および組成物 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562251016P | 2015-11-04 | 2015-11-04 | |
| US62/251,016 | 2015-11-04 | ||
| USPCT/US2016/14918 | 2016-01-26 | ||
| PCT/US2016/014918 WO2016123100A1 (en) | 2015-01-26 | 2016-01-26 | Methods and compositions for inducing hematopoietic cell differentiation |
| US201662337093P | 2016-05-16 | 2016-05-16 | |
| US62/337,093 | 2016-05-16 | ||
| PCT/US2016/044122 WO2017078807A1 (en) | 2015-11-04 | 2016-07-26 | Methods and compositions for inducing hematopoietic cell differentiation |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022000188A Division JP2022058480A (ja) | 2015-11-04 | 2022-01-04 | 造血細胞分化を誘導するための方法および組成物 |
| JP2024015135A Division JP2024054194A (ja) | 2015-11-04 | 2024-02-02 | 造血細胞分化を誘導するための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018533363A JP2018533363A (ja) | 2018-11-15 |
| JP2018533363A5 true JP2018533363A5 (enExample) | 2019-09-05 |
| JP7534070B2 JP7534070B2 (ja) | 2024-08-14 |
Family
ID=58662624
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018521543A Active JP7534070B2 (ja) | 2015-11-04 | 2016-07-26 | 造血細胞分化を誘導するための方法および組成物 |
| JP2022000188A Pending JP2022058480A (ja) | 2015-11-04 | 2022-01-04 | 造血細胞分化を誘導するための方法および組成物 |
| JP2024015135A Pending JP2024054194A (ja) | 2015-11-04 | 2024-02-02 | 造血細胞分化を誘導するための方法および組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022000188A Pending JP2022058480A (ja) | 2015-11-04 | 2022-01-04 | 造血細胞分化を誘導するための方法および組成物 |
| JP2024015135A Pending JP2024054194A (ja) | 2015-11-04 | 2024-02-02 | 造血細胞分化を誘導するための方法および組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (6) | US10858628B2 (enExample) |
| EP (1) | EP3371301A4 (enExample) |
| JP (3) | JP7534070B2 (enExample) |
| KR (2) | KR102773713B1 (enExample) |
| CN (2) | CN115927199A (enExample) |
| AU (3) | AU2016348342B2 (enExample) |
| CA (1) | CA3003152A1 (enExample) |
| SG (1) | SG11201803145RA (enExample) |
| WO (1) | WO2017078807A1 (enExample) |
Families Citing this family (121)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016123100A1 (en) | 2015-01-26 | 2016-08-04 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| SG10202110908WA (en) | 2015-05-04 | 2021-11-29 | Cytomx Therapeutics Inc | Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof |
| KR20180033537A (ko) | 2015-07-21 | 2018-04-03 | 더 칠드런스 메디칼 센터 코포레이션 | Pd-l1 발현 조혈 줄기 세포 및 용도 |
| WO2017078807A1 (en) * | 2015-11-04 | 2017-05-11 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| CN108368520B (zh) | 2015-11-04 | 2023-01-17 | 菲特治疗公司 | 多能细胞的基因组工程改造 |
| WO2017123806A1 (en) | 2016-01-12 | 2017-07-20 | Cedars-Sinai Medical Center | A method of non destructive monitoring of biological processes in microfluidic tissue culture systems |
| EP3405568A4 (en) | 2016-01-20 | 2019-12-04 | Fate Therapeutics, Inc. | COMPOUNDS AND METHODS FOR IMMUNOCELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES |
| SG11201805186VA (en) | 2016-01-20 | 2018-07-30 | Fate Therapeutics Inc | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| GB2564582B (en) | 2016-02-01 | 2021-09-22 | Emulate Inc | Systems and methods for growth of intestinal cells in microfluidic devices |
| ES3039670T3 (en) * | 2016-04-15 | 2025-10-23 | Memorial Sloan Kettering Cancer Center | Transgenic t cell and chimeric antigen receptor t cell compositions and related methods |
| JP7215994B2 (ja) | 2016-09-06 | 2023-01-31 | ザ チルドレンズ メディカル センター コーポレーション | 人工多能性幹細胞由来の免疫細胞 |
| JP7098615B2 (ja) | 2016-12-05 | 2022-07-11 | フェイト セラピューティクス，インコーポレイテッド | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| WO2018140647A1 (en) | 2017-01-25 | 2018-08-02 | Cedars-Sinai Medical Center | In vitro induction of mammary-like differentiation from human pluripotent stem cells |
| JP7092281B2 (ja) * | 2017-02-07 | 2022-06-28 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | 多能性幹細胞から模倣自然免疫細胞を生成する方法及びキット |
| CA3052473A1 (en) | 2017-02-09 | 2018-08-16 | Indapta Therapeutics, Inc. | Engineered natural killer (nk) cells and compositions and methods thereof |
| US11767513B2 (en) | 2017-03-14 | 2023-09-26 | Cedars-Sinai Medical Center | Neuromuscular junction |
| AU2018234827B2 (en) * | 2017-03-15 | 2024-04-04 | Orca Biosystems Inc. | Compositions and methods for hematopoietic stem cell transplants |
| WO2018176001A2 (en) | 2017-03-24 | 2018-09-27 | Cedars-Sinai Medical Center | Methods and compositions for production of fallopian tube epithelium |
| US20210102167A1 (en) * | 2017-04-26 | 2021-04-08 | Kyoto University | Hematopoietic progenitor cell marker |
| SG11202000105QA (en) | 2017-07-14 | 2020-02-27 | Cytomx Therapeutics Inc | Anti-cd166 antibodies and uses thereof |
| CA3071683A1 (en) * | 2017-08-08 | 2019-02-14 | Sangamo Therapeutics, Inc. | Chimeric antigen receptor mediated cell targeting |
| KR102167548B1 (ko) | 2017-09-21 | 2020-10-19 | 한국생명공학연구원 | 자연살해세포의 제조방법 및 그의 용도 |
| US11879137B2 (en) | 2017-09-22 | 2024-01-23 | The Children's Medical Center Corporation | Treatment of type 1 diabetes and autoimmune diseases or disorders |
| US20200308540A1 (en) * | 2017-09-29 | 2020-10-01 | Regents Of The University Of Minnesota | Methods of making, expanding, and using a human progenitor t cell |
| BR112020007228A2 (pt) | 2017-10-11 | 2020-10-13 | Fate Therapeutics, Inc. | reprogramação celular usando sistema de expressão de vetor plasmídeo temporal e transitório |
| KR20250048610A (ko) | 2017-12-22 | 2025-04-09 | 페이트 세러퓨틱스, 인코포레이티드 | 향상된 면역 효과기 세포 및 이의 용도 |
| CN112041428B (zh) * | 2018-01-18 | 2024-05-24 | 新加坡科技研究局 | 用于在悬浮培养物中分化人多能干细胞系的方法 |
| US12161676B2 (en) | 2018-03-23 | 2024-12-10 | Cedars-Sinai Medical Center | Methods of use of islet cells |
| JP7464532B2 (ja) | 2018-04-06 | 2024-04-09 | シーダーズ－サイナイ メディカル センター | マイクロ流体チップ上のヒト多能性幹細胞由来の神経変性疾患モデル |
| WO2019195800A1 (en) | 2018-04-06 | 2019-10-10 | Cedars-Sinai Medical Center | Novel differentiation technique to generate dopaminergic neurons from induced pluripotent stem cells |
| US20210033628A1 (en) * | 2018-04-30 | 2021-02-04 | Cedars-Sinai Medical Center | Diagnostic and drug screening for molecular signatures of early onset sporadic parkinson's disease |
| EP3831936A4 (en) * | 2018-07-31 | 2022-04-13 | Thyas Co. Ltd. | METHOD FOR PRODUCING A REGENERATED T LYMPHOCYTE POPULATION USING IPS CELLS |
| AU2019336221B2 (en) | 2018-09-07 | 2025-05-15 | Wisconsin Alumni Research Foundation | Generation of hematopoietic progenitor cells from human pluripotent stem cells |
| JP7716976B2 (ja) * | 2018-09-19 | 2025-08-01 | フジフィルム セルラー ダイナミクス，インコーポレイテッド | キメラ抗原受容体改変免疫細胞の活性化及び拡大培養のためのプロテインｌ |
| US11591390B2 (en) | 2018-09-27 | 2023-02-28 | Celgene Corporation | SIRP-α binding proteins and methods of use thereof |
| TW202028237A (zh) | 2018-09-27 | 2020-08-01 | 美商西建公司 | SIRPα結合蛋白及其使用方法 |
| CN109266618B (zh) * | 2018-10-18 | 2021-04-23 | 赛元生物科技(杭州)有限公司 | 能够靶向肿瘤细胞的巨噬细胞及其制备方法 |
| US12410402B2 (en) | 2018-11-21 | 2025-09-09 | Indapta Therapeutics, Inc. | Methods for expansion of natural killer (NK) cell subset and related compositions and methods |
| SG11202105480WA (en) | 2018-12-02 | 2021-06-29 | Fate Therapeutics Inc | IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS |
| CA3127593A1 (en) * | 2019-01-22 | 2020-07-30 | Washington University | Compositions and methods for generating hematopoietic stem cells (hscs) |
| EP3924467A1 (en) | 2019-02-15 | 2021-12-22 | Editas Medicine, Inc. | Modified natural killer (nk) cells for immunotherapy |
| KR20220004126A (ko) * | 2019-04-26 | 2022-01-11 | 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 | 유도 다능성 줄기 세포로부터 생체내에서 기능적이고 환자-특이적인 흉선 조직의 생성 |
| WO2020227677A1 (en) * | 2019-05-09 | 2020-11-12 | Figene, Llc | Fibroblast generated patient-specific vaccines |
| CN110106144B (zh) * | 2019-05-17 | 2021-10-08 | 苏州大学 | 一种诱导造血干细胞向前t系细胞分化的方法和试剂盒 |
| WO2021024170A1 (en) * | 2019-08-05 | 2021-02-11 | Voloshin Sela Tali | Increasing cancer cells' sensitivity to tumor treating fields (ttfields) by inhibiting il11 activity |
| GB201911953D0 (en) * | 2019-08-20 | 2019-10-02 | Adaptimmune Ltd | T cell production fram RAG inacivated iPSCs |
| MX2022001961A (es) * | 2019-08-20 | 2022-03-11 | Adaptimmune Ltd | Medio de cultivo para induccion de hematopoyesis. |
| GB201911957D0 (en) * | 2019-08-20 | 2019-10-02 | Adaptimmune Ltd | Methods of producing haemogenic progenitor cells from pluripotent stem cells |
| IL291924A (en) * | 2019-10-07 | 2022-06-01 | Fate Therapeutics Inc | Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof |
| JP7664913B2 (ja) * | 2019-10-17 | 2025-04-18 | フェイト セラピューティクス，インコーポレイテッド | 免疫のための増強されたキメラ抗原受容体エフェクター細胞操作およびその使用 |
| WO2021096218A1 (ko) * | 2019-11-13 | 2021-05-20 | 연세대학교 산학협력단 | 혈관 내피세포 순수 분리 방법, 혈관 내피세포 특성 유지 배지 및 이를 포함하는 배양 방법 |
| EP4058564A1 (en) * | 2019-11-14 | 2022-09-21 | Amgen Inc. | Hematopoietic precursor cell production |
| KR20220113422A (ko) * | 2019-11-28 | 2022-08-12 | 암니오틱스 아베 | 내피에서 조혈로의 이행 동안 최종 계통 선별화를 유도하는 대사작용 |
| CA3171960A1 (en) * | 2020-02-28 | 2021-09-02 | Purdue Research Foundation | Generating aorta-gonad-mesonephros-like hematopoietic cells from human pluripotent stem cells under a defined condition |
| CN115427555A (zh) * | 2020-02-28 | 2022-12-02 | 武田药品工业株式会社 | 由多能干细胞产生自然杀伤细胞的方法 |
| EP4133058A4 (en) * | 2020-04-06 | 2024-05-08 | The Board of Trustees of the Leland Stanford Junior University | GENERATING POPULATIONS OF HUMAN BLOOD AND BLOOD VESSEL PROGENITORS FROM PLURIPOTENT STEM CELLS |
| CA3176416A1 (en) * | 2020-04-21 | 2021-10-28 | Modassir CHOUDHRY | Cellular vaccine platform and methods of use |
| MX2022015863A (es) | 2020-06-19 | 2023-03-23 | Fate Therapeutics Inc | Combinación de tipos de células efectoras derivadas de células madre pluripotentes inducidas (ipsc) para uso en inmunoterapia. |
| CN111808812B (zh) * | 2020-08-31 | 2020-12-15 | 首都医科大学附属北京友谊医院 | 一种用于多能干细胞向造血干细胞分化的材料和方法 |
| CN116507346A (zh) * | 2020-09-24 | 2023-07-28 | 广州辑因医疗科技有限公司 | 化合物用于提高人造血干细胞移植效率的用途 |
| CN112119977B (zh) * | 2020-10-15 | 2021-10-19 | 中国人民解放军军事科学院军事医学研究院 | Cd317诱导的抑郁和记忆损伤的小鼠模型的构建方法及其应用 |
| US20250262301A1 (en) | 2020-10-26 | 2025-08-21 | Shoreline Biosciences, Inc. | Methods of inducing antibody-dependent cellular cytotoxicity (adcc) using modified natural killer (nk) cells |
| CN114525257A (zh) * | 2020-10-30 | 2022-05-24 | 未来智人再生医学研究院(广州)有限公司 | 一种表达Tim-3阻断物的多能干细胞或其衍生物及应用 |
| US11459372B2 (en) | 2020-11-30 | 2022-10-04 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| TW202237827A (zh) | 2020-12-03 | 2022-10-01 | 美商世紀治療股份有限公司 | 經基因工程改造之細胞及其用途 |
| JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス，インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
| KR102681869B1 (ko) * | 2020-12-18 | 2024-07-05 | 차의과학대학교 산학협력단 | 줄기 세포를 모니터링하기 위한 조성물, 키트, 및 이를 이용한 줄기 세포를 모니터링하는 방법 |
| US11473060B2 (en) | 2020-12-30 | 2022-10-18 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into NK cells |
| MX2023008809A (es) | 2021-01-29 | 2023-08-04 | Allogene Therapeutics Inc | ATENUACIÓN O INACTIVACIÓN DE UNO O MÁS DE TAP2, NLRC5, ß2M, TRAC, RFX5, RFXAP Y RFXANK PARA MITIGAR EL RECONOCIMIENTO DE CÉLULAS T DE PRODUCTOS CELULARES ALOGÉNICOS. |
| KR102766602B1 (ko) * | 2021-02-05 | 2025-02-13 | 의료법인 성광의료재단 | 다능성 줄기세포 유래 조혈 내피세포를 이용한 유전자 편집된 세포의 제조방법 |
| EP4293107A4 (en) * | 2021-02-05 | 2025-10-08 | Sungkwang Medical Found | METHOD FOR DIFFERENTIATING HEMOGENIC ENDOTHELIAL CELLS DERIVED FROM PLURIPOTENT STEM CELLS INTO LYMPHOID LINEAGE CELLS |
| GB202102297D0 (en) * | 2021-02-18 | 2021-04-07 | Adaptimmune Ltd | Methods of Producing Haemogenic Endothelial Cells from Pluripotent Stem Cells |
| CN112831461B (zh) * | 2021-02-26 | 2023-08-08 | 澳门大学 | 一种诱导干细胞分化成中胚层谱系或滋养细胞谱系的方法及药物 |
| AU2022257812A1 (en) * | 2021-04-12 | 2023-10-12 | Medgene Therapeutics, Inc. | Method for activating and proliferating cd8 t cells exposed to antigen, cd8 t cells, prepared thereby, having enhanced anticancer activity, and use thereof |
| US12617864B2 (en) | 2021-04-12 | 2026-05-05 | Medgene Therapeutics, Inc. | Methods of activating and proliferating exhausted CD8 T cells, CD8 T cells with enhanced activity prepared by the same, and uses thereof |
| EP4326852A4 (en) * | 2021-04-22 | 2025-04-23 | Artec Biotech, Inc. | Method for producing hematopoietic cells from stem cells using vascular organoids |
| AU2022272317A1 (en) * | 2021-05-14 | 2023-11-30 | Appia Bio, Inc. | Production of engineered t cells from stem cells |
| WO2022264033A1 (en) * | 2021-06-15 | 2022-12-22 | Takeda Pharmaceutical Company Limited | Method for producing natural killer cells from pluripotent stem cells |
| CN117836405A (zh) * | 2021-08-13 | 2024-04-05 | 先声创新公司 | 三维培养多能干细胞产生造血干细胞 |
| JP2024529729A (ja) * | 2021-08-19 | 2024-08-08 | シーダーズ－サイナイ メディカル センター | 加齢関連疾患および神経変性疾患の予防および処置におけるｉＰＳＣ由来免疫細胞 |
| WO2023038436A1 (ko) * | 2021-09-10 | 2023-03-16 | 의료법인 성광의료재단 | 전분화능 줄기세포 유래 조혈모세포 제조방법 및 상기 제조된 조혈모세포를 이용한 인간화 마우스 모델 제작방법 |
| CN113801846B (zh) * | 2021-09-22 | 2024-06-04 | 南京艾尔普再生医学科技有限公司 | 一种从人诱导多能干细胞分化为自然杀伤细胞的方法 |
| WO2023102119A1 (en) * | 2021-12-01 | 2023-06-08 | The Brigham And Women's Hospital, Inc. | Multispecific t cell engager polypeptides in combination with t cells for cancer therapy |
| CN118829724A (zh) * | 2022-01-20 | 2024-10-22 | 科济生物医药（上海）有限公司 | 诱导细胞分化的方法 |
| CN114350608B (zh) * | 2022-01-27 | 2024-05-28 | 昭泰英基生物医药（香港）有限公司 | 一种诱导t细胞重编程为类nk细胞的组合物及其应用 |
| AU2023241513A1 (en) * | 2022-04-01 | 2024-10-17 | Therabest Co.,Ltd | Natural killer cells produced from induced pluripotent stem cells, method for producing same, and use thereof |
| JP7707304B2 (ja) | 2022-04-08 | 2025-07-14 | フェイト セラピューティクス，インコーポレイティド | 腫瘍標的化のためのキメラ抗原受容体 |
| KR20250005097A (ko) | 2022-04-08 | 2025-01-09 | 페이트 세러퓨틱스, 인코포레이티드 | 고형 종양 표적화 골격을 갖는 세포 및 이의 용도 |
| CN114702591B (zh) * | 2022-05-17 | 2022-09-23 | 诺赛联合(北京)生物医学科技有限公司 | 成体细胞衍生的类器官制备技术 |
| KR102759886B1 (ko) | 2022-06-16 | 2025-02-05 | 대한민국 | Dusp6가 결핍된 줄기세포 및 이의 용도 |
| CN114774365B (zh) * | 2022-06-16 | 2022-08-23 | 呈诺再生医学科技(北京)有限公司 | 一种诱导iPSC分化获得CD34+细胞和NK细胞的方法及其应用 |
| CN119053690A (zh) * | 2022-06-20 | 2024-11-29 | 上海优替济生生物医药有限公司 | 体外诱导干细胞样记忆细胞的化合物及其应用 |
| WO2023247722A1 (en) * | 2022-06-22 | 2023-12-28 | Fondazione Telethon Ets | Method for isolating hemogenic endothelial cells |
| CN114958771B (zh) * | 2022-06-27 | 2023-12-05 | 广东康盾创新产业集团股份公司 | 一种ipsc-car-nk细胞的制备方法 |
| WO2024020587A2 (en) | 2022-07-22 | 2024-01-25 | Tome Biosciences, Inc. | Pleiopluripotent stem cell programmable gene insertion |
| WO2024036105A2 (en) * | 2022-08-11 | 2024-02-15 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Method for generating cells of the t cell lineage with engineering broadly reactive human notch ligand |
| KR20250069893A (ko) * | 2022-09-13 | 2025-05-20 | 알.피.쉐러 테크놀러지즈 엘엘씨 | 만능성 줄기 세포를 조혈 전구 세포 및 줄기 세포로 분화시키는 방법 |
| CA3267211A1 (en) * | 2022-09-14 | 2024-03-21 | Fate Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
| KR20240069648A (ko) * | 2022-11-10 | 2024-05-20 | 의료법인 성광의료재단 | 전분화능 줄기세포에서 자연살해세포로의 분화 유도용 배지 조성물 및 이를 이용한 분화 방법 |
| WO2024127335A1 (en) * | 2022-12-15 | 2024-06-20 | Janssen Biotech, Inc. | Materials, methods and systems for cellular redifferentiation and expansion |
| KR20250160941A (ko) * | 2023-02-16 | 2025-11-14 | 신택스 바이오, 인크. | 조혈 계통으로의 세포 프로그래밍을 위한 시스템 및 이의 방법 |
| WO2024220222A1 (en) * | 2023-04-21 | 2024-10-24 | The Regents Of The University Of California | Media and methods for differentiating t cells from hematopoietic stem cells |
| CN116445408B (zh) * | 2023-05-22 | 2024-02-02 | 呈诺再生医学科技(北京)有限公司 | LSD1抑制剂在促进iPSC向HSC分化和HSC干性维持中的应用 |
| JPWO2024248141A1 (enExample) * | 2023-06-02 | 2024-12-05 | ||
| CN116574672B (zh) * | 2023-07-11 | 2023-10-20 | 北京北启生物医药有限公司 | 一种诱导化学诱导多能干细胞向生血内皮细胞分化的培养基及方法 |
| WO2025062293A1 (en) * | 2023-09-22 | 2025-03-27 | Janssen Biotech, Inc. | Methods and materials for scalable 3d cellular redifferentiation |
| CN117050940B (zh) * | 2023-10-11 | 2024-01-26 | 苏州艾凯利元生物科技有限公司 | 一种制备自然杀伤细胞的方法 |
| CN117106714B (zh) * | 2023-10-11 | 2024-01-26 | 苏州艾凯利元生物科技有限公司 | 一种制备b细胞的方法 |
| CN117050941B (zh) * | 2023-10-11 | 2024-01-26 | 苏州艾凯利元生物科技有限公司 | 一种制备自然杀伤细胞的方法 |
| CN117448269B (zh) * | 2023-10-25 | 2025-06-17 | 中国科学院香港创新研究院再生医学与健康创新中心 | 一种诱导人多能干细胞快速分化为巨噬细胞的方法及应用 |
| AU2024368655A1 (en) * | 2023-10-26 | 2026-04-02 | Amgen Inc. | Pluripotent cell differentiation |
| CN117736988B (zh) * | 2023-12-25 | 2024-06-21 | 深圳泽医细胞治疗集团有限公司 | 用于诱导Tscm细胞的培养基、培养方法及其应用 |
| WO2025210582A1 (en) * | 2024-04-04 | 2025-10-09 | Janssen Biotech, Inc. | Materials, methods and systems for cellular redifferentiation and expansion |
| GB202405750D0 (en) * | 2024-04-24 | 2024-06-05 | Plasticell Ltd | Therapy |
| WO2025235862A1 (en) | 2024-05-10 | 2025-11-13 | Inndura Therapeutics Inc. | A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a |
| WO2025238202A1 (en) * | 2024-05-16 | 2025-11-20 | Novo Nordisk A/S | Production of cryonoids and blood cells derived therefrom. |
| CN118325837B (zh) * | 2024-06-12 | 2024-09-03 | 深圳市中佳生物医疗科技有限公司 | 中性粒细胞的无血清无基质细胞培养方法 |
| WO2026062399A1 (en) * | 2024-09-19 | 2026-03-26 | Lift Biosciences Ltd | Granulocytes and granulocyte precursors |
| GB202413831D0 (en) * | 2024-09-19 | 2024-11-06 | Lift Biosciences Ltd | Therapeutic cells |
Family Cites Families (111)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5523226A (en) | 1993-05-14 | 1996-06-04 | Biotechnology Research And Development Corp. | Transgenic swine compositions and methods |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US5780300A (en) | 1995-09-29 | 1998-07-14 | Yale University | Manipulation of non-terminally differentiated cells using the notch pathway |
| GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| JP3626206B2 (ja) | 1997-06-13 | 2005-03-02 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | Ｓｍａｄ６及びその使用 |
| AU757046B2 (en) | 1997-07-01 | 2003-01-30 | Warner-Lambert Company | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors |
| US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| BR0108545A (pt) | 2000-02-24 | 2004-06-29 | Xcyte Therapies Inc | Estimulação e concentração simultâneas das células |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| WO2002006213A2 (en) | 2000-07-19 | 2002-01-24 | Warner-Lambert Company | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| JP2002060786A (ja) | 2000-08-23 | 2002-02-26 | Kao Corp | 硬質表面用殺菌防汚剤 |
| US6689744B2 (en) | 2000-09-22 | 2004-02-10 | Genentech, Inc. | Notch receptor agonists and uses |
| WO2002059285A1 (en) | 2000-10-27 | 2002-08-01 | Fred Hutchinson Cancer Research Center | Methods for immortalizing cells |
| WO2003016496A2 (en) | 2001-08-20 | 2003-02-27 | The Scripps Research Institute | Zinc finger binding domains for cnn |
| EP1456380B1 (en) | 2001-11-02 | 2012-04-18 | Giuliani International Limited | Smad7 inhibitors for the treatment of cns diseases |
| US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
| TWI343377B (en) | 2002-03-13 | 2011-06-11 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| US7575925B2 (en) | 2002-12-10 | 2009-08-18 | Sunnybrook Health Sciences Centre | Cell preparations comprising cells of the T cell lineage and methods of making and using them |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| NZ547481A (en) | 2003-11-19 | 2009-12-24 | Array Biopharma Inc | Heterocyclic inhibitors of mek and methods of use thereof |
| US7972854B2 (en) | 2004-02-05 | 2011-07-05 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| CA2568344C (en) | 2004-05-27 | 2016-01-19 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
| US20070036769A9 (en) | 2004-06-03 | 2007-02-15 | Linheng Li | BMP pathway methods and compositions |
| CN102898364A (zh) | 2005-05-18 | 2013-01-30 | 阵列生物制药公司 | Mek的杂环抑制剂及其使用方法 |
| US20090186076A1 (en) | 2006-02-01 | 2009-07-23 | Kazunori Kataoka | Combined Use of TGF-Beta Signaling Inhibitor and Antitumor Agent |
| MX373998B (es) | 2006-03-24 | 2020-07-22 | Childrens Medical Center | Uso de un modulador de células madre hematopoyeticas (hsc) para promover el crecimiento de hsc. |
| EP2044056B1 (en) | 2006-07-14 | 2012-08-22 | Novartis AG | Pyrimidine derivatives as alk-5 inhibitors |
| WO2008094597A2 (en) | 2007-01-30 | 2008-08-07 | University Of Georgia Research Foundation, Inc. | Early mesoderm cells, a stable population of mesendoderm cells that has utility for generation of endoderm and mesoderm lineages and multipotent migratory cells (mmc) |
| PL2856876T3 (pl) | 2007-03-30 | 2018-06-29 | Memorial Sloan-Kettering Cancer Center | Konstytutywna ekspresja ligandów kostymulujących na limfocytach T poddanych transferowi adoptywnemu |
| WO2009091826A2 (en) | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) |
| WO2009097140A1 (en) | 2008-01-30 | 2009-08-06 | Memorial Sloan-Kettering Cancer Center | Methods for off -the -shelf tumor immunotherapy using allogeneic t-cell precursors |
| WO2009104825A1 (en) * | 2008-02-18 | 2009-08-27 | Kaist | Method for inducing the defferentiation of embryonic stem cells into hemangioblast |
| EP2712921B1 (en) | 2008-05-06 | 2018-07-11 | Astellas Institute for Regenerative Medicine | Hemangio colony forming cells and non-engrafting hemangio cells |
| ES2489040T3 (es) | 2008-12-03 | 2014-09-01 | The Scripps Research Institute | Cultivos de células madre |
| US8993343B2 (en) | 2009-01-28 | 2015-03-31 | Korea Research Institute Of Bioscience And Biotechnology | CD93 or use of soluble fragment thereof |
| EP2398897B1 (en) * | 2009-02-20 | 2017-06-28 | Cellular Dynamics International, Inc. | Methods and compositions for the differentiation of stem cells |
| CN102388130B (zh) | 2009-02-27 | 2014-08-27 | 细胞动力国际有限公司 | 多能细胞的分化 |
| CA2756833C (en) | 2009-04-09 | 2019-11-19 | Sangamo Therapeutics, Inc. | Targeted integration into stem cells |
| US9005968B2 (en) | 2009-10-16 | 2015-04-14 | The Scripps Research Institute | Induction of pluripotent cells |
| NO2510096T3 (enExample) | 2009-12-10 | 2015-03-21 | ||
| US9206394B2 (en) | 2010-02-03 | 2015-12-08 | The University Of Tokyo | Method for reconstructing immune function using pluripotent stem cells |
| JPWO2011096482A1 (ja) | 2010-02-03 | 2013-06-13 | 国立大学法人 東京大学 | 多能性幹細胞を用いた免疫機能再建法 |
| JP5777115B2 (ja) * | 2010-03-18 | 2015-09-09 | 国立大学法人京都大学 | 多能性幹細胞から中胚葉細胞への分化誘導法 |
| EP3399026B1 (en) | 2010-06-14 | 2024-06-26 | The Scripps Research Institute | Reprogramming of cells to a new fate |
| WO2011159684A2 (en) | 2010-06-15 | 2011-12-22 | Cellular Dynamics International, Inc. | Generation of induced pluripotent stem cells from small volumes of peripheral blood |
| CA3157027A1 (en) | 2010-07-21 | 2012-01-26 | Sangamo Therapeutics, Inc. | Methods and compositions for modification of a t-cell receptor gene |
| CN103180434A (zh) | 2010-08-05 | 2013-06-26 | 威斯康星校友研究基金会 | 用于人多能细胞培养的简化基础培养基 |
| EP2603227B1 (en) | 2010-08-12 | 2017-10-04 | Fate Therapeutics, Inc. | Improved hematopoietic stem and progenitor cell therapy |
| US9181529B2 (en) | 2010-10-19 | 2015-11-10 | Cellular Dynamics International, Inc. | Titration of differentiation medium components |
| PE20170917A1 (es) | 2010-12-20 | 2017-07-12 | Genentech Inc | Anticuerpos anti-mesotelina e inmunoconjugados |
| AU2011349446C1 (en) | 2010-12-22 | 2016-01-21 | Fate Therapauetics, Inc. | Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs |
| WO2012089669A1 (en) | 2010-12-31 | 2012-07-05 | Universität Für Bodenkultur Wien | Method of generating induced pluripotent stem cells and differentiated cells |
| US8700106B2 (en) | 2011-03-09 | 2014-04-15 | Universal Electronics Inc. | System and method for provision of infrared signalling in smart phone devices |
| CN102732483B (zh) * | 2011-03-31 | 2014-12-03 | 北京大学 | 造血祖细胞的制备方法及其专用培养基 |
| US20130071414A1 (en) | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
| WO2013009825A1 (en) | 2011-07-11 | 2013-01-17 | Cellular Dynamics International, Inc. | Methods for cell reprogramming and genome engineering |
| KR101405437B1 (ko) * | 2011-08-16 | 2014-06-11 | 사회복지법인 삼성생명공익재단 | 줄기세포 유래 미세소포를 포함하는 신경 생성 촉진용 조성물 |
| WO2013028684A1 (en) * | 2011-08-23 | 2013-02-28 | Wisconsin Alumni Research Foundation | Angiohematopoietic progenitor cells |
| CN102329769B (zh) * | 2011-09-28 | 2013-07-31 | 浙江大学 | 一种获得造血干细胞的方法 |
| WO2013074916A1 (en) | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| WO2013075222A1 (en) * | 2011-11-21 | 2013-05-30 | University Health Network | Populations of hematopoietic progenitors and methods of enriching stem cells therefor |
| PT2785834T (pt) | 2011-12-02 | 2020-11-13 | Fate Therapeutics Inc | Composição de células estaminais melhorada |
| US9428732B2 (en) * | 2011-12-05 | 2016-08-30 | Primorigen Biosciences, Inc. | Compositions and methods for differentiating pluripotent stem cells into primitive blood cells and uses thereof |
| EP2788476B1 (en) | 2011-12-08 | 2019-05-22 | Fred Hutchinson Cancer Research Center | Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells |
| EP2606884A1 (en) | 2011-12-21 | 2013-06-26 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Inhibitors of notch signaling pathway and use thereof in treatment of cancers |
| DK2836226T3 (en) * | 2012-02-24 | 2017-09-18 | Hutchinson Fred Cancer Res | COMPOSITIONS AND PROCEDURES FOR TREATING HEMOGLOBINOPATHY |
| PL2838548T3 (pl) | 2012-04-17 | 2024-02-05 | University Of Washington Through Its Center For Commercialization | Komórki z niedoborem hla klasy ii, komórki z niedoborem hla klasy i, zdolne do ekspresji białek hla klasy ii i ich zastosowania |
| WO2013158309A2 (en) | 2012-04-18 | 2013-10-24 | The Board Of Trustees Of The Leland Stanford Junior University | Non-disruptive gene targeting |
| US9260696B2 (en) | 2012-04-24 | 2016-02-16 | Dan S. Kaufman | Method for developing natural killer cells from stem cells |
| EP2853590B1 (en) | 2012-05-22 | 2018-11-07 | The University of Tokyo | Method for producing antigen-specific t cells |
| EP4541818A3 (en) | 2012-05-25 | 2025-07-23 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
| US20150148292A1 (en) | 2012-07-09 | 2015-05-28 | Emory University | Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto |
| SG11201502598SA (en) | 2012-10-02 | 2015-05-28 | Sloan Kettering Inst Cancer | Compositions and methods for immunotherapy |
| SG11201503045YA (en) | 2012-10-19 | 2015-05-28 | Agency Science Tech & Res | Methods of differentiating stem cells into one or more cell lineages |
| US9382531B2 (en) * | 2012-10-22 | 2016-07-05 | Wisconsin Alumni Research Foundation | Induction of hemogenic endothelium from pluripotent stem cells |
| US9255250B2 (en) | 2012-12-05 | 2016-02-09 | Sangamo Bioscience, Inc. | Isolated mouse or human cell having an exogenous transgene in an endogenous albumin gene |
| CN114558032B (zh) * | 2012-12-21 | 2025-07-29 | 安斯泰来再生医药协会 | 由多能干细胞制备血小板的方法及其组合物 |
| SG11201507275TA (en) | 2013-03-13 | 2015-10-29 | Wisconsin Alumni Res Found | Methods and materials for hematoendothelial differentiation of human pluripotent stem cells under defined conditions |
| JP6857028B2 (ja) | 2013-03-15 | 2021-04-14 | メモリアル スローン ケタリング キャンサー センター | 免疫治療のための組成物および方法 |
| US9943545B2 (en) | 2013-03-15 | 2018-04-17 | Fate Therapeutics, Inc. | Stem cell culture media and methods of enhancing cell survival |
| WO2014165707A2 (en) | 2013-04-03 | 2014-10-09 | Memorial Sloan-Kettering Cancer Center | Effective generation of tumor-targeted t-cells derived from pluripotent stem cells |
| JP2016522679A (ja) * | 2013-04-04 | 2016-08-04 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ＣＲＩＳＰＲ／Ｃａｓ系を用いたゲノム編集の治療的使用 |
| US9381210B2 (en) * | 2013-04-15 | 2016-07-05 | Wisconsin Alumni Research Foundation | Induced pluripotent stem cell model of chronic myeloid leukemia revealed olfactomedin 4 as a novel therapeutic target in leukemia stem cells |
| US10240126B2 (en) * | 2013-06-12 | 2019-03-26 | Kyoto University | Induced pluripotent stem cell selection method and method for inducing differentiation to blood cells |
| CN103361310B (zh) * | 2013-06-25 | 2015-09-23 | 中国人民解放军军事医学科学院野战输血研究所 | 培养基、试剂盒及其用途 |
| CA2926078C (en) | 2013-10-17 | 2021-11-16 | Sangamo Biosciences, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells |
| US9932607B2 (en) | 2013-11-15 | 2018-04-03 | The Board Of Trustees Of The Leland Stanford Junior University | Site-specific integration of transgenes into human cells |
| SG11201606934SA (en) | 2014-03-04 | 2016-09-29 | Fate Therapeutics Inc | Improved reprogramming methods and cell culture platforms |
| EP3122769B1 (en) | 2014-03-28 | 2023-02-22 | Regents of the University of Minnesota | Polypeptides, cells, and methods involving engineered cd16 |
| WO2015164740A1 (en) | 2014-04-24 | 2015-10-29 | Board Of Regents, The University Of Texas System | Application of induced pluripotent stem cells to generate adoptive cell therapy products |
| CN103937743B (zh) * | 2014-04-27 | 2017-12-01 | 浙江大学 | 一种利用三维诱导系统获得造血干细胞的方法 |
| WO2016123100A1 (en) | 2015-01-26 | 2016-08-04 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| EP3250682A4 (en) | 2015-01-26 | 2018-08-01 | Fate Therapeutics, Inc. | Cells with increased immuno-regulatory properties and methods for their use and manufacture |
| CN104745529B (zh) * | 2015-03-13 | 2019-03-05 | 华南生物医药研究院 | 瘦素在诱导胚胎干细胞分化为造血干/祖细胞中的用途及其应用 |
| US20170020922A1 (en) * | 2015-07-16 | 2017-01-26 | Batu Biologics Inc. | Gene editing for immunological destruction of neoplasia |
| EP4108255A1 (en) | 2015-10-05 | 2022-12-28 | Precision Biosciences, Inc. | Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene |
| WO2017078807A1 (en) | 2015-11-04 | 2017-05-11 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| CN108368520B (zh) | 2015-11-04 | 2023-01-17 | 菲特治疗公司 | 多能细胞的基因组工程改造 |
| WO2017164257A1 (ja) * | 2016-03-23 | 2017-09-28 | 国立大学法人京都大学 | 血球分化能の高い中胚葉誘導方法 |
| ES3039670T3 (en) | 2016-04-15 | 2025-10-23 | Memorial Sloan Kettering Cancer Center | Transgenic t cell and chimeric antigen receptor t cell compositions and related methods |
-
2016
- 2016-07-26 WO PCT/US2016/044122 patent/WO2017078807A1/en not_active Ceased
- 2016-07-26 SG SG11201803145RA patent/SG11201803145RA/en unknown
- 2016-07-26 CN CN202211397675.5A patent/CN115927199A/zh active Pending
- 2016-07-26 CA CA3003152A patent/CA3003152A1/en active Pending
- 2016-07-26 AU AU2016348342A patent/AU2016348342B2/en active Active
- 2016-07-26 KR KR1020187015759A patent/KR102773713B1/ko active Active
- 2016-07-26 JP JP2018521543A patent/JP7534070B2/ja active Active
- 2016-07-26 US US15/773,519 patent/US10858628B2/en active Active
- 2016-07-26 EP EP16862624.0A patent/EP3371301A4/en active Pending
- 2016-07-26 KR KR1020257005830A patent/KR20250033315A/ko active Pending
- 2016-07-26 CN CN201680073326.4A patent/CN108473961B/zh active Active
-
2020
- 2020-10-02 US US17/062,478 patent/US10947505B2/en active Active
- 2020-10-02 US US17/062,475 patent/US11162075B2/en active Active
-
2021
- 2021-03-11 US US17/199,301 patent/US11162076B2/en active Active
- 2021-03-12 US US17/200,351 patent/US12410403B2/en active Active
-
2022
- 2022-01-04 JP JP2022000188A patent/JP2022058480A/ja active Pending
-
2023
- 2023-06-20 AU AU2023203874A patent/AU2023203874B2/en active Active
-
2024
- 2024-02-02 JP JP2024015135A patent/JP2024054194A/ja active Pending
-
2025
- 2025-08-08 US US19/295,444 patent/US20260035664A1/en active Pending
-
2026
- 2026-03-02 AU AU2026201575A patent/AU2026201575A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7440027B2 (ja) | 多能性幹細胞から免疫細胞療法用ｔ細胞を誘導する方法 | |
| CN107922925B (zh) | 用于自然杀伤细胞扩增的方法 | |
| CN108473961B (zh) | 用于诱导造血细胞分化的方法和组合物 | |
| CA3205479A1 (en) | Engineered gamma delta t cells and methods of making and using thereof | |
| US20250230411A1 (en) | Method for producing regulatory t cells | |
| CN107002036A (zh) | 用于建立具有编码抗原特异性t细胞受体的基因的多能性干细胞的方法 | |
| KR20240037179A (ko) | 만능 줄기 세포-유래 조혈 계통 | |
| US20260124241A1 (en) | Modified hematopoietic stem cells and progenies thereof | |
| CN120641557A (zh) | 来源于多能细胞的红系谱系 | |
| CN115087732B (zh) | 来自人T细胞来源的iPS细胞的细胞毒性T细胞 | |
| JP2025533909A (ja) | 多能性細胞に由来するｂ細胞系統 | |
| CN120615119A (zh) | 用于同种异体细胞疗法以覆盖全球、种族或特定疾病群体的免疫相容细胞 | |
| Smerchansky et al. | Engineered multicellular niches for pluripotent stem cell–derived immunotherapy | |
| CN120641114A (zh) | 多能干细胞来源的巨核细胞和血小板 | |
| JP2023553531A (ja) | 造血幹細胞を生成する方法及びその組成物 | |
| CN117940139A (zh) | 对用于同种异体car t细胞疗法的干细胞进行工程化 | |
| US20250332260A1 (en) | Immune compatible cells for allogeneic cell therapies to cover global, ethnic, or disease-specific populations | |
| US20250361487A1 (en) | Natural killer cell lineages derived from pluripotent cells | |
| CN120303393A (zh) | 多能干细胞来源的t细胞群体及其祖细胞 | |
| JP2026506126A (ja) | 既製の細胞療法のための多能性幹細胞操作免疫細胞 | |
| WO2025257119A1 (en) | Method of producing a modified immune cell from a pluripotent stem cell (psc) | |
| WO2025104248A1 (en) | Method of producing an immune cell devoid of endogenous effector functions from pluripotent stem cells | |
| Ma | Derivation of Lymphocytes from Human induced Pluripotent Stem Cells |